EcoDrugPlus

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSEEEG00000020464
Gene Symbol: HTR2CL1
2 Cross references
202 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSEEEG00000009527
Gene Symbol: HTR5AB
4 Cross references
198 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSEEEG00000012175
Gene Symbol: HTR1B
2 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSEEEG00000001967
Gene Symbol: HTR1B
4 Cross references
183 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSEEEG00000024123
Gene Symbol: HTR1E
4 Cross references
150 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSEEEG00000013175
Gene Symbol: HTR1F
2 Cross references
143 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSEEEG00000008979
Gene Symbol: HTR2A
4 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSEEEG00000011122
Gene Symbol: HTR2A
4 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSEEEG00000020620
Gene Symbol: LOC113582305
3 Cross references
155 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSEEEG00000004581
Gene Symbol: HTR3A
4 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSEEEG00000004579
Gene Symbol: HTR3B
4 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSEEEG00000014266
Gene Symbol: HTR4
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).